Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical pharmacology and therapy

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/cpt.463PMID 27564568PMCID PMC5309133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.

  2015cited by this paper
• Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.

  2015influential reference
• Considerations for rare variants in drug metabolism genes and the clinical implications

  2014cited by this paper
• Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.

  2014cited by this paper
• Changes in Gene Expression Associated with FTO Overexpression in Mice

  2014cited by this paper
• Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.

  2014cited by this paper
• Pharmacogenomic diversity in Singaporean populations and Europeans

  2014cited by this paper
• PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.

  2012cited by this paper
• The effects of EBV transformation on gene expression levels and methylation profiles.

  2011cited by this paper
• The Obesity Related Gene, FTO, Interacts with APOE, and is Associated with Alzheimer's Disease Risk: A Prospective Cohort Study

  2011cited by this paper
• Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

  2011cited by this paper
• METAL: fast and efficient meta-analysis of genomewide association scans

  2010cited by this paper
• Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.

  2009cited by this paper
• Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

  2009cited by this paper
• Adverse reactions to azathioprine cannot be predicted by thiopurine S‐methyltransferase genotype in Japanese patients with inflammatory bowel disease

  2009cited by this paper
• Treating childhood acute lymphoblastic leukemia without cranial irradiation.

  2009cited by this paper
• Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity.

  2009cited by this paper
• The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics

  2008influential reference
• Genetic Analysis of Human Traits In Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines

  2008cited by this paper
• Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study.

  2008cited by this paper
• A Common Variant in the FTO Gene Is Associated with Body Mass Index and Predisposes to Childhood and Adult Obesity

  2007cited by this paper
• Thiopurine Treatment in Inflammatory Bowel Disease

  2007cited by this paper
• Thiopurine Treatment in Inflammatory Bowel Disease

  2007cited by this paper
• Using HapMap Tools in Pharmacogenomic Discovery: The Thiopurine Methyltransferase Polymorphism

  2007cited by this paper
• Thiopurine methyltransferase in acute lymphoblastic leukemia.

  2006cited by this paper
• [International HapMap project].

  2005cited by this paper
• Comprehensive Screening of the Thiopurine Methyltransferase Polymorphisms by Denaturing High-Performance Liquid Chromatography

  2005cited by this paper
• Haploview: analysis and visualization of LD and haplotype maps

  2005cited by this paper
• Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.

  2004cited by this paper
• A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A Pediatric Oncology Group study (now The Children's Oncology Group)

  2004cited by this paper
• Consequences of binding an S-adenosylmethionine analogue on the structure and dynamics of the thiopurine methyltransferase protein backbone.

  2004cited by this paper
• Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age

  2004cited by this paper
• Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

  2003cited by this paper
• Preventing Toxicity With a Gene Test

  2003cited by this paper
• Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.

  2003cited by this paper
• The International HapMap Project

  2003cited by this paper
• Differences Between Children and Adults in Thiopurine Methyltransferase Activity and Metabolite Formation During Thiopurine Therapy: Possible Role of Concomitant Methotrexate

  2002cited by this paper
• Human thiopurine methyltransferase activity varies with red blood cell age.

  2001cited by this paper
• Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

  2000cited by this paper
• Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

  2000cited by this paper
• Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

  1999cited by this paper
• Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

  1999cited by this paper
• Polymorphism of the thiopurine S-methyltransferase gene in African-Americans.

  1999cited by this paper
• Thiopurine methyltransferase alleles in British and Ghanaian populations.

  1999cited by this paper
• Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia

  1999cited by this paper
• Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter.

  1998cited by this paper
• Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms

  1997cited by this paper
• Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance

  1997cited by this paper
• Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.

  1996cited by this paper
• Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.

  1995cited by this paper
• Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults.

  1995cited by this paper
• Thiopurine methyltransferase activity in American white subjects and black subjects

  1994cited by this paper
• Thiopurine methyltransferase activity in a sample population of black subjects in Florida

  1993cited by this paper
• Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

  1990cited by this paper
• Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity

  1982cited by this paper

• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update.

  2026cites this paper
• The role of pharmacogenetics in the therapy regimen of acute lymphoblastic leukemia in children: recent discoveries and future perspectives

  2026cites this paper
• Thiopurine S-methyltransferase - An important intersection of drug-drug interactions in thiopurine treatment.

  2025cites this paper
• Association of DPP4 Gene Variants with Classic and DPP4 Inhibitor-Associated Bullous Pemphigoid

  2025cites this paper
• Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.

  2024cites this paper
• TPMT*8: A Decreased Function Allele Important in Thiopurine Metabolism.

  2024cites this paper
• Pharmacogenomics polygenic risk score: Ready or not for prime time?

  2024cites this paper
• Quantification of Thiopurine Metabolites in Human Erythrocytes by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

  2024cites this paper
• Pharmacogenetics and Cancer Treatment: Progress and Prospects

  2023cites this paper
• SERS spectroscopy as a tool for the study of thiopurine drug pharmacokinetics in a model of human B leukemia cells.

  2023cites this paper
• Can Pharmacogenetic Variants in TPMT, MTHFR and SLCO1B1 Genes Be Used as Potential Markers of Outcome Prediction in Systemic Sclerosis Patients?

  2023cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• Prominence of NUDT15 genetic variation associated with 6‐mercaptopurine tolerance in a genome‐wide association study of Japanese children with acute lymphoblastic leukaemia

  2022cites this paper
• Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers

  2022cites this paper
• Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers

  2021cites this paper
• Biomarkers for gastrointestinal adverse events related to thiopurine therapy

  2021cites this paper
• Disparities in acute lymphoblastic leukemia risk and survival across the lifespan in the United States of America

  2021cites this paper
• Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies

  2021cites this paper
• Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia

  2021cites this paper
• Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy

  2021cites this paper
• Association between the TPMT*3C (rs1142345) Polymorphism and the Risk of Death in the Treatment of Acute Lymphoblastic Leukemia in Children from the Brazilian Amazon Region

  2020cites this paper
• Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism

  2020cites this paper
• Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population

  2020cites this paper
• Pharmacogenetic studies of thiopurine methyltransferase genotype‐phenotype concordance and effect of methotrexate on thiopurine metabolism

  2020cites this paper
• Pharmacogenetic determinants of thiopurines in an Indian cohort

  2020cites this paper
• Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia.

  2020cites this paper
• Identification of rare defective allelic variants in cases of thiopurine S-methyltransferase deficient activity.

  2020cites this paper
• Pharmacogenomics and ALL treatment: How to optimize therapy.

  2020cites this paper
• The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn’s Disease

  2020cites this paper
• PGPM_A_279446 665..671

  2020cites this paper
• NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease.

  2019cites this paper
• PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients

  2019cites this paper
• Pharmacogenetics of thiopurines

  2019cites this paper
• Pharmacogenetics and Cancer Treatment: Progress and Prospects

  2019cites this paper
• The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics

  2019cites this paper
• Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment

  2019cites this paper
• Combined evaluation of genotype and phenotype of thiopurine S-methyltransferase (TPMT) in the clinical management of patients in chronic therapy with azathioprine

  2019cites this paper
• Pharmacogenetics and Cancer Treatment: Progress and Prospects

  2019cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

  2019cites this paper
• Methylation of selenocysteine catalysed by thiopurine S-methyltransferase.

  2019cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update

  2018cites this paper
• Pharmacogenetics of treatments for inflammatory bowel disease

  2018cites this paper
• Applications of Pharmacogenomics in Oncology

  2018cites this paper
• Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring

  2018cites this paper
• The Pharmacogenetics of Immune-Modulating Therapy.

  2018cites this paper
• Combination of common and novel rare NUDT15 variants improves predictive sensitivity of thiopurine-induced leukopenia in children with acute lymphoblastic leukemia

  2018cites this paper
• Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing

  2018cites this paper
• Multicentric Case–Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease

  2017cites this paper
• Bringing a genomic perspective to the safety of drug treatment in oncology

  2017cites this paper
• Role of Genetic Variations in Determining Treatment Outcome in Head and Neck Cancer

  2017cites this paper
• One amino acid makes a difference–Characterization of a new TPMT allele and the influence of SAM on TPMT stability

  2017cites this paper
• Personalized medicine: Genetic risk prediction of drug response

  2017influential citation
• Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity

  2017cites this paper